Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2015

01-07-2015 | Epidemiology

The association between breast cancer and thyroid cancer: a meta-analysis

Authors: Kyle R. Joseph, Senarath Edirimanne, Guy D. Eslick

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

Previous studies have suggested an association between breast cancer and thyroid cancer; however, there has not been a formal meta-analysis which collates the existing evidence supporting the hypothesis that breast cancer or thyroid cancer predisposes an individual to developing the other. A systematic search was carried out using PubMed and Medline. We searched for articles containing epidemiological evidence of breast cancer following thyroid cancer and vice versa. Additionally, we searched for articles that included epidemiological data involving the incidence of all second primary malignancies (SPMs) following both breast cancer and thyroid cancer, and compared the datasets. The meta-analysis performed in a total of 18 studies showed that there is a significantly increased risk of developing thyroid cancer as a second primary malignancy of breast cancer (SIR = 1.59, 95 % confidence interval (CI) 1.28–1.99). Additionally, there was marginally increased risk of developing breast cancer as a second primary malignancy of thyroid cancer (SIR = 1.24, 95 % CI 1.16–1.33), compared to the general risk of developing a second primary malignancy following thyroid cancer. The findings suggest that the risk of developing thyroid cancer as a second primary malignancy of breast cancer and vice versa is increased compared to the background risk of developing other SPMs. The risk of developing thyroid cancer after a primary breast cancer was higher than the risk of developing breast cancer as a second primary malignancy of thyroid cancer. This suggests that the effects of treatment-related factors and specific pathological processes of each cancer may contribute to the increased risk rather than common risk factors including genetic factors. Elucidation of the common mechanisms between breast cancer and thyroid cancer will have important implications in both diagnostic and therapeutic management of these cancers. Benefit of thyroid ultrasound screening after breast cancer surgery needs to be assessed.
Literature
1.
2.
3.
Davies L, Welch H (2006) Increasing incidence of thyroid cancer in the united states, 1973–2002. JAMA 295(18):2164–2167CrossRefPubMed
4.
Xu F et al (2009) Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases. Zhongguo Dang Dai Er Ke Za Zhi 11(2):120–123PubMed
5.
Tubiana M (2009) Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 91(1):4–15 Discussion 1–3 CrossRefPubMed
6.
Yu J et al (2009) Fine-needle aspiration of breast carcinoma metastatic to follicular variant of papillary thyroid carcinoma. Diagn Cytopathol 37(9):665–666CrossRefPubMed
7.
Robison LL (2009) Treatment-associated subsequent neoplasms among long-term survivors of childhood cancer: the experience of the Childhood Cancer Survivor Study. Pediatr Radiol 39(Suppl 1):S32–S37CrossRefPubMed
8.
Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117(2):281–288CrossRefPubMed
9.
Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr 68:99–112PubMed
10.
McTiernan A, Weiss NS, Daling JR (1987) Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. Cancer Res 47(1):292–295PubMed
11.
Murakami R et al (1987) Second primary cancers following female breast cancer in Osaka, Japan—a population-based cohort study. Jpn J Clin Oncol 17(4):293–302PubMed
12.
Hrafnkelsson J et al (1989) Papillary thyroid carcinoma in Iceland. A study of the occurrence in families and the coexistence of other primary tumours. Acta Oncol 28(6):785–788CrossRefPubMed
13.
Stein M et al (1989) Multiple primary thyroid and breast cancer in Israel, 1960–1976. S Afr Med J 76(12):664–666PubMed
14.
Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8(5):764–770CrossRefPubMed
15.
Vassilopoulou-Sellin R et al (1999) Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 85(3):696–705CrossRefPubMed
16.
Li CI et al (2000) Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control 11(9):805–811CrossRefPubMed
17.
Chen AY et al (2001) The development of breast carcinoma in women with thyroid carcinoma. Cancer 92(2):225–231CrossRefPubMed
18.
Tanaka H et al (2001) Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 92(1):1–8CrossRefPubMed
19.
Agrawal S, Eng C (2006) Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet 15(5):777–787CrossRefPubMed
20.
Ngeow J et al (2014) Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 32(17):1818–1824CrossRefPubMedPubMedCentral
21.
22.
Yalavarthi S et al (2014) Metachronous malignancies in head and neck region: report of two cases. Indian J Pathol Microbiol 57(2):314–316CrossRefPubMed
23.
Park CM et al (2014) The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer. Ann Surg Treat Res 86(4):169–176CrossRefPubMedPubMedCentral
24.
Castinetti F et al (2014) Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 15(6):648–655CrossRefPubMed
25.
Hsu CH et al (2014) Co-occurrence of second primary malignancy in patients with thyroid cancer. QJM 107(8):643–648CrossRefPubMed
26.
27.
Canchola AJ, Horn-Ross PL, Purdie DM (2006) Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163(6):521–527CrossRefPubMed
28.
Berthe E et al (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31(5):685–691CrossRefPubMed
29.
Brown AP et al (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93(2):504–515CrossRefPubMed
30.
Sandeep TC et al (2006) Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91(5):1819–1825CrossRefPubMed
31.
Verkooijen RB et al (2006) The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155(6):801–806CrossRefPubMed
32.
Hall P, Holm LE, Lundell G (1990) Second primary tumors following thyroid cancer. A Swedish record-linkage study. Acta Oncol 29(7):869–873CrossRefPubMed
33.
Johns ME et al (1986) Multiple primary neoplasms in patients with salivary gland or thyroid gland tumors. Laryngoscope 96(7):718–721CrossRefPubMed
34.
35.
Kim C et al (2013) The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid 23(5):575–582CrossRefPubMedPubMedCentral
36.
Lu CH et al (2013) Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur J Endocrinol 169(5):577–585CrossRefPubMed
37.
Rubino C et al (2003) Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 107(5):791–796CrossRefPubMed
38.
Sadetzki S et al (2003) Second primary breast and thyroid cancers (Israel). Cancer Causes Control 14(4):367–375CrossRefPubMed
39.
Consorti F et al (2011) Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World J Surg Oncol 9:88CrossRefPubMedPubMedCentral
40.
Schottenfeld D, Berg J (1971) Incidence of multiple primary cancers. IV. Cancers of the female breast and genital organs. J Natl Cancer Inst 46(1):161–170PubMed
41.
Evans HS et al (2001) Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 84(3):435–440CrossRefPubMedPubMedCentral
42.
Schwartz A et al (1989) Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 14(2):245–254CrossRefPubMed
43.
Schenker JG, Levinsky R, Ohel G (1984) Multiple primary malignant neoplasms in breast cancer patients in Israel. Cancer 54(1):139–144CrossRef
44.
Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.1. Lancet 148(3802):104–107CrossRef
45.
Subramanian S et al (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17(12):1277–1288CrossRefPubMed
46.
Sawka AM et al (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19(5):451–457CrossRefPubMed
47.
48.
Schenker JG, Levinsky R, Ohel G (1984) Multiple primary malignant neoplasms in breast cancer patients in Israel. Cancer 54(1):145–150CrossRefPubMed
49.
Longy M, Lacombe D (1996) Cowden disease. Report of a family and review. Ann Genet 39(1):35–42PubMed
Metadata
Title
The association between breast cancer and thyroid cancer: a meta-analysis
Authors
Kyle R. Joseph
Senarath Edirimanne
Guy D. Eslick
Publication date
01-07-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3456-6

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue

Letter to the Editor

Letter to the Editor Re: Bundred et al. “Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer”

Brief Report

Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer

Brief Report

Assessing absolute changes in breast cancer risk due to modifiable risk factors

Brief Report

Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis

Clinical Trial

Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography

Epidemiology

Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits